This page shows the latest SCLC news and features for those working in and with pharma, biotech and healthcare.
The US Food and Drug Administration (FDA) granted Keytruda (pembrolizumab) an accelerated approval for the treatment of third line SCLC in June 2019. ... However, the SCLC market has been cornered by rival checkpoint inhibitors, including Roche’s
The new dosing regimen is consistent with Imfinzi’s approved dosing in extensive-stage small cell lung cancer (ES-SCLC). ... of 10mg/kg approval in NSCLC and the CASPIAN phase 3 trial which used a four-week fixed-dose regimen in ES-SCLC.
The drug scored conditional approved as a monotherapy in the metastatic, second-line setting for SCLC by the US Food and Drug Administration (FDA) n June. ... We look forward to the further development of lurbinectedin in SCLC and other tumours, both as
Although Keytruda holds much of the NSCLC market, other immunotherapies have carved out niches in other indications – in particular the less common lung cancer type, small cell lung cancer (SCLC). ... This includes Roche’s Tecentriq, which is
That includes Roche’s PD-L1 inhibitor Tecentriq (atezolizumab) which is approved for first-line SCLC. ... SCLC accounts for around 10-15% of all cases of lung cancer and has a poor prognosis with a five-year survival rate of approximately 6% across all
Merck &Co’s checkpoint inhibitor Keytruda (pembrolizumab) currently holds much of the NSCLC market, although the drug failed to show benefit in SCLC when added to chemotherapy. ... The disappointing results in SCLC marred an otherwise dominant position
More from news
Approximately 6 fully matching, plus 34 partially matching documents found.
triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer. .
Rova-T showed a 44% overall response rate in DLL-expressing small cell lung cancer (SCLC) patients who had failed one or more standard therapies.
July finalised a $730m exclusive deal with Boehringer Ingelheim for HM61713, an orally active third generation EGFR agent in small cell lung cancer (SCLC).
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...